l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial

References

• Hu L, Shen H, Wu QF, et al. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. Clin Exp Obstet Gynecol. 2014;41:288–292.
   PubMed Web of Science ®Google Scholar
• Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2014;6:1–13.
   Web of Science ®Google Scholar
• Valsamakis G, Lois K, Kumar S, et al. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). Hormones (Athens). 2013;12:363–378.
   PubMedGoogle Scholar
• Cho LW, Kilpatrick ES, Keevil BG, et al. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2009;70:233–237.
   PubMed Web of Science ®Google Scholar
• Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32:343–353.
   PubMed Web of Science ®Google Scholar
• Barber TM, Dimitriadis GK, Andreou A, et al. Polycystic ovary syndrome: insight into pathogenesis and a common association with insulin resistance. Clin Med (Lond). 2016;16:262–266.
   PubMed Web of Science ®Google Scholar
• Roe A, Hillman J, Butts S, et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab. 2014;99:E841–E847.
   PubMed Web of Science ®Google Scholar
• Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr Opin Obstet Gynecol. 2010;22:466–476.
   PubMed Web of Science ®Google Scholar
• Johnson N. Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome – a met analysis of randomized trials. Aust N Z J Obstet Gynecol. 2011;51:125–129.
   PubMed Web of Science ®Google Scholar
• El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015;116:107–112.
   PubMed Web of Science ®Google Scholar
• Ringseis R, Eder K, Keller J. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr. 2012;51:1–18.
   PubMed Web of Science ®Google Scholar
• Fenkci SM, Fenkci V, Oztekin O, et al. Serum total l-carnitine levels in non-obese women with polycystic ovary syndrome. Hum Reprod. 2008;23:1602–1606.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Brown J, Farquhar C, Beck J, et al. Clomiphene and antiestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009;4:CD002249.
   Google Scholar
• Ismail AM, Hamed AH, Saso S, et al. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol. 2014;180:148–152.
   PubMed Web of Science ®Google Scholar
• Tang T, Glanville J, Hayden CJ, et al. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome: a randomized, placebo controlled, double-blind multicenter study. Hum Reprod. 2006;21:80–89.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Res. 2012;33:981–1030.
   Web of Science ®Google Scholar
• Bjelica A, Bjelanović J, Milić N, et al. Algorithm of ovulation induction in patients with polycistic ovary syndrome. Med Pregl. 2016;69:25–30.
   PubMedGoogle Scholar
• Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016;22:687–708.
   PubMed Web of Science ®Google Scholar
• Legro RS. Ovulation induction in polycystic ovary syndrome: current options. Best Pract Res Clin Obstet Gynecol. 2016;37:152–159.
   PubMed Web of Science ®Google Scholar
• Costello MF, Misso ML, Wong J, et al. The treatment of infertility in polycystic ovary syndrome: a brief update. Aust N Z J Obstet Gynaecol. 2012;52:400–403.
   PubMed Web of Science ®Google Scholar
• Tagliaferri V, Romualdi D, Immediata V, et al. Metformin vs. myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. Clin Endocrinol (Oxf). 2017;86:725–730.
   PubMed Web of Science ®Google Scholar
• Yang PK, Hsu CY, Chen MJ, et al. The efficacy of 24-month metformin for improving menses, hormones, and metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab. 2018;103:890–899.
   PubMed Web of Science ®Google Scholar
• Lord JM, Flight IH, Norman RJ. Insulin sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;3:CD003053.
   Google Scholar
• Tan S, Hahn S, Benson S, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol. 2007;157:669–676.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009;15:57–68.
   PubMed Web of Science ®Google Scholar
• Tang T, Lord JM, Norman RJ, et al. Insulin-sensitizing drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhea and subfertility. Cochrane Database Syst Rev. 2012;5:CD003053.
   PubMed Web of Science ®Google Scholar
• Shahebrahimi K, Jalilian N, Bazgir N, et al. Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome. Indian J Endocr Metab. 2016;20:805–809.
   PubMedGoogle Scholar
• Naderpoor N, Shorakae S, de Courten B, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;2:560–574.
   Google Scholar
• Patel R, Shah G. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2017;33:1545–1557.
   PubMed Web of Science ®Google Scholar
• Bredella MA, McManus S, Misra M. Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. Clin Endocrinol (Oxf). 2013;79:199–203.
   PubMed Web of Science ®Google Scholar
• Emami Naini A, Moradi M, Mortazavi M, et al. Effects of oral L-carnitine supplementation on lipid profile, anemia, and quality of life in chronic renal disease patients under hemodialysis: a randomized, double-blinded, placebo-controlled trial. J Nutr Metab. 2012;2012:510483.
   PubMedGoogle Scholar
• Samimi M, Jamilian M, Ebrahimi FA, et al. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2016; 84:851–857.
   PubMed Web of Science ®Google Scholar
• Gao J, Zhou L, Hong J, et al. Assessment of insulin resistance in Chinese PCOS patients with normal glucose tolerance. Gynecol Endocrinol. 2017;4:1–4.
   Google Scholar
• Zahra M, Shah M, Ali A, et al. Effects of metformin on endocrine and metabolic parameters in patients with polycystic ovary syndrome. Horm Metab Res. 2017;49:103–108.
   PubMed Web of Science ®Google Scholar
• Wall BT, Stephens FB, Constantin-Teodosiu D, et al. Chronic oral ingestion of L-carnitine and carbohydrate increases muscle carnitine content and alters muscle fuel metabolism during exercise in humans. J Physiol. 2011;589:963–973.
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, van der Meer IM, Remuzzi G. Oral acetyl-L-carnitine therapy and insulin resistance. Hypertension. 2010;55:e26.
   PubMed Web of Science ®Google Scholar
• Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene. 2014;533:469–476.
   PubMed Web of Science ®Google Scholar
• Kuşçu NK, Var A. Oxidative stress but not endothelial dysfunction exists in non-obese, young group of patients with polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2009;88:612–617.
   PubMed Web of Science ®Google Scholar
• Jamilian H, Jamilian M, Samimi M, et al. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol. 2017;33:442–447.
   PubMed Web of Science ®Google Scholar
• Özer A, Bakacak M, Kıran H, et al. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekol Pol. 2016;87:733–738.
   PubMed Web of Science ®Google Scholar
• Celik F, Kose M, Yilmazer M, et al. Plasma L-carnitine levels of obese and non-obese polycystic ovary syndrome patients. J Obstet Gynaecol. 2017;37:476–479.
   PubMedGoogle Scholar